<DOC>
	<DOCNO>NCT00062335</DOCNO>
	<brief_summary>RATIONALE : Using computer system create 3-dimensional picture tumor plan treatment may enable doctor provide effective radiation therapy cause less damage normal tissue . PURPOSE : This phase I trial study side effect best dose high-dose 3-dimensional conformal radiation therapy treat patient inoperable stage I , stage II , stage IIIA non-small cell lung cancer .</brief_summary>
	<brief_title>High-Dose 3-Dimensional Conformal Radiation Therapy Treating Patients With Inoperable Stage I , Stage II , Stage IIIA Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine optimal dose high-dose 3-dimensional conformal radiotherapy patient inoperable stage I , II , IIIA non-small cell lung cancer treat accord total lung volume irradiate . - Determine feasibility regimen , term local control rate incidence distant metastasis , patient . OUTLINE : This open-label , nonrandomized , dose-escalation , multicenter study . Patients assign 1 3 stratum accord total lung volume irradiate ( less 25 % vs 25-37 % vs 37 % ) . - Stratum I : Patients undergo high-dose 3-dimensional ( 3-D ) conformal radiotherapy 5 day week 6 week . - Stratum II : Patients undergo high-dose 3-D conformal radiotherapy 5 day week 5.5-7 week . - Stratum III : Patients undergo high-dose 3-D conformal radiotherapy 5 day week 5.5-6.5 week . Cohorts 6-15 patient stratum receive escalate dose intensity high-dose 3-D conformal radiotherapy ( either increase total dose shorten treatment time ) maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 , 2 15 , 3 30 patient experience dose-limiting toxicity . Patients follow 1 month , least every 2 month 1 year , every 3 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 54-135 patient ( 18-45 per stratum ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Medically inoperable stage I II disease Stage III disease eligible provide follow true : No supraclavicular node involvement No peripherally locate low lobe tumor AND contralateral upper mediastinal node involvement No distant metastasis No malignant pleural pericardial effusion PATIENT CHARACTERISTICS : Age Not specify Performance status WHO 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular No prior myocardial infarction No prior complete bundle branch block No prior cardiovascular disease result New York Heart Association class III IV heart disease No clinically significant cardiac arrhythmia No congestive heart failure Pulmonary FEV_1 least 1.2 L OR DLCO least 60 % Other No prior concurrent malignancy except cure basal cell skin cancer carcinoma situ cervix No intractable uncontrolled infection No psychological , familial , social , geographical condition would preclude study compliance followup Able tolerate course radiotherapy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 3 week since prior chemotherapy No prior anthracyclines No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy chest area Surgery No prior therapeutic surgery chest area Other No prior therapy chest area</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
</DOC>